XML 24 R6.htm IDEA: XBRL DOCUMENT v3.8.0.1
Condensed Consolidated Statements of Shareholders' Equity (Deficit) (Unaudited) - USD ($)
$ in Thousands
Total
Series A
Series B
Preferred Shares of Beneficial Interest Series A
Preferred Shares of Beneficial Interest Series A
Series A
Common Shares of Beneficial Interest
Paid-in Capital
Paid-in Capital
Series A
Accumulated Deficit and Distributions in Excess of Net Earnings
Accumulated Deficit and Distributions in Excess of Net Earnings
Series A
Accumulated Deficit and Distributions in Excess of Net Earnings
Series B
Accumulated Other Comprehensive Loss
Increase (Decrease) in Stockholders' Equity [Roll Forward]                        
Net loss $ 4,384                      
Other comprehensive loss 3,616                      
Ending balance at Mar. 31, 2017                       $ (6,928)
Beginning balance (in shares) at Dec. 31, 2017       125   69,370,609            
Beginning balance at Dec. 31, 2017 (186,924)     $ 0   $ 694 $ 394,082   $ (581,470)     (230)
Increase (Decrease) in Stockholders' Equity [Roll Forward]                        
Net loss (8,639)               (8,639)      
Other comprehensive loss (938)                     (938)
Redemption and distributions on preferred shares of beneficial interest – Series A   $ (134)           $ (133)   $ (1)    
Redemption of and distribution on preferred shares of beneficial interest – Series A (in shares)         (125)              
Distributions on preferred shares of beneficial interest – Series B     $ (1,817)               $ (1,817)  
Distributions on common shares (21,436)               (21,436)      
Stock-based compensation expense, net of exercise (Stock Options and Restricted Stock Units) 1,580         $ 1 1,579          
Stock-based compensation expense (Stock Options and Restricted Stock Units, net of exercise) (in shares)           125,763            
Stock-based compensation expense (modification of Restricted Stock Units) 2,600           2,600          
Warrants exercise 0         $ 64 (64)          
Warrants exercise (in shares)           6,426,818            
Issuance of common shares 484,905         $ 334 484,571          
Issuance of common stock (in shares)           33,350,000            
Conversion of mezzanine Series B Preferred shares 372,791         $ 332 372,459          
Conversion of mezzanine Series B Preferred shares (in shares)           33,240,258            
Ending balance at Mar. 31, 2018 $ 641,988     $ 0   $ 1,425 $ 1,255,094   $ (613,363)     $ (1,168)
Ending balance (in shares) at Mar. 31, 2018       0   142,513,448